UNSPSC 51282949: Trovafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C20H15F3N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9F388J00UK, chemically known as cp-99,219 but generally known as trovafloxacin, which bears US NIH Compound Identifier 62959. European Medicines Agency schedules Trovafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11350MIG.

UNSPSC 51282949 Trovafloxacin, a Commodity code, represents pharmaceutical products sourced through state and local health procurement channels. The recent opportunities tagged to this code show state and local governments purchasing antibiotics and emergency medical supplies — including fluoroquinolone antibiotics (ciprofloxacin, doxycycline) and naloxone — through piggyback contracts, cooperative purchasing consortiums, and competitive sealed bids. Issuing bodies include state departments of public health and county health authorities; the Illinois Department of Public Health and Seminole County, Florida both appear in recent award activity. These procurements typically require vendors to meet federal compliance standards (E-Verify, drug-free workplace certification), maintain specified insurance coverage, and deliver on fixed-fee or unit-pricing bases with initial terms of 12 to 24 months plus renewal options.

The code shows activity in at least Illinois and Florida as of mid-2026. Representative recent opportunities include the Illinois Department of Public Health's August 2026 piggyback award through the MMCAP Infuse consortium to Chartwell Rx LLC for doxycycline hyclate and ciprofloxacin hydrochloride tablets totaling $2,999,999.11 over the contract life (awarded under Invitation for Bid 26-482DPH-PREPD-B-53392), and Seminole County's June 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Cooperative purchasing vehicles such as MMCAP Infuse appear to be an active channel for bulk pharmaceutical procurement by state health agencies.